XIAP inhibitor and antiestrogen embelin abrogates metastasis and augments apoptosis in estrogen receptor positive human breast adenocarcinoma cell line MCF-7 |
| |
Authors: | K. R. Sumalatha G. Abiramasundari G. K. Chetan T. Divya G. Sudhandiran M. Sreepriya |
| |
Affiliation: | 1. Department of Microbiology and Biotechnology, Bangalore University, Jnana Bharathi Campus, Bangalore, 560056, Karnataka, India 2. Department of Human Genetics, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, 560029, Karnataka, India 3. Department of Biochemistry, University of Madras, Guindy Campus, Chennai, 600023, Tamil Nadu, India
|
| |
Abstract: | Tamoxifen therapy for the treatment of hormone responsive breast cancer has limitations due to acquired resistance in the case of recurrences. Embelin, a known inhibitor of X-linked inhibitor of apoptosis protein (XIAP) was also reported to exhibit strong antiestrogenic effects in animal models. Dual role of embelin as a proapoptotic and antiestrogenic agent may have potential benefits in the therapy of breast cancer. In this study, the effects of embelin treatment on estrogen receptor positive Human breast adenocarcinoma (MCF-7) cells was investigated to primarily understand if embelin being an antiestrogen and XIAP inhibitor could be a potential alternative to tamoxifen therapy. Results revealed that, embelin at a concentration of 65 μg/ml attenuated proliferation, inhibited metastatic migration, modulated the expression of Bcl2, Caspases and induced apoptosis in MCF-7 cells which was found to be p53 mediated. Hence, chemotherapy with embelin could be a promising strategy to be experimented in hormone responsive breast cancers. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|